Does Rallies show 13F holders for PRCT?

Yes. Rallies tracks hedge fund and 13F ownership data for PRCT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PRCT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PRCT. It does not provide personalized investment advice.

PRCT (PROCEPT BioRobotics Corporation Common Stock) Stock Analysis - Hedge Fund Holdings

PROCEPT BioRobotics Corporation Common Stock (PRCT) is a publicly traded Healthcare sector company. As of May 21, 2026, PRCT trades at $28.15 with a market cap of $1.48B and a P/E ratio of -16.03. PRCT moved +8.57% today. Year to date, PRCT is -15.13%; over the trailing twelve months it is -52.50%. Its 52-week range spans $19.35 to $103.81. Analyst consensus is buy with an average price target of $36.50. Rallies surfaces PRCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PRCT stock?

Hedge funds tracked by Rallies that own PRCT include Centerbook Partners and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for PROCEPT BioRobotics Corporation Common Stock.

PRCT Key Metrics

Key financial metrics for PRCT
Metric	Value
Price	$28.15
Market Cap	$1.48B
P/E Ratio	-16.03
EPS	$-1.72
Dividend Yield	0.00%
52-Week High	$103.81
52-Week Low	$19.35
Volume	58
Avg Volume	0
Revenue (TTM)	$308.05M
Net Income	$-95.57M
Gross Margin	63.70%

Top Hedge Funds Holding PRCT

Centerbook Partners holds 52.67K shares of PRCT, changed +0.00% as of Mar 31, 2026.
Mangrove Partners holds 10.22K shares of PRCT, changed +0.00% as of Sep 30, 2024.

Latest PRCT News

AUA Guidelines Back Aquablation for 30–150 mL Prostates with 5-Year Data — May 14, 2026
PROCEPT BioRobotics Q1 Revenue Jumps 20% to $83.1M with 30% Procedure Growth — Apr 29, 2026
Sonder Capital Closes Futures II with Mayo Clinic and Sutter Health Backing — Mar 24, 2026
EAU Upgrades Aquablation Therapy to Strong Recommendation Over TURP for BPH — Mar 23, 2026
PROCEPT BioRobotics Launches AI-Enabled HYDROS System in UK, Plans 2026 Expansion — Mar 12, 2026

Recent PRCT Insider Trades

Nouri Alaleh sold 3.03K (~$78.26K) on Mar 19, 2026.
Nouri Alaleh sold 2.33K (~$60.97K) on Mar 19, 2026.
Nouri Alaleh sold 304 (~$8.56K) on Mar 17, 2026.

PRCT Analyst Consensus

11 analysts cover PRCT: 0 strong buy, 7 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $36.50.

Common questions about PRCT

Who owns PRCT stock?: Hedge funds tracked by Rallies that own PRCT include Centerbook Partners and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for PROCEPT BioRobotics Corporation Common Stock.
Does Rallies show 13F holders for PRCT?: Yes. Rallies tracks hedge fund and 13F ownership data for PRCT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PRCT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PRCT. It does not provide personalized investment advice.